Novo Nordisk stock edges lower as Medicare Part D pricing negotiations pressure outlook

Traders Union
All News
Financial News
Novo Nordisk slides 1.69% today

Highlights

Novo Nordisk faces projected 2026 adjusted sales decline of 5% to 13% due to Medicare Part D pricing and restructuring costs near 8 billion Danish kroner.
Competition risk increased as Amazon's direct-to-consumer entry amplifies pricing pressure on Novo Nordisk's GLP-1 obesity drug Wegovy.
Shares are under persistent selling pressure with weak trend signals, trading in a $37.80 to $39.40 range and further downside favored.

Guidance cut and Amazon’s entry intensify pricing and sector risk

Novo Nordisk continues to face pricing headwinds from Medicare Part D negotiations and is managing restructuring costs estimated at approximately 8 billion Danish kroner. The company’s full-year 2026 guidance projected adjusted sales growth between negative 5% and negative 13% at constant exchange rates. Uncertainty in the GLP-1 obesity drug market intensified as Amazon announced its entry into the weight-loss drug sector through a new direct-to-consumer program, raising pricing pressure on Novo Nordisk’s key medication, Wegovy. Earnings are scheduled to be reported on May 6, though price action has remained under broader selling pressure.

Mixed daily momentum amid technical support test and selling pressure

On the technical chart, NVO is positioned below the MA-20 ($37.95) and MA-50 ($39.74), and well under the MA-200 ($51.05). The Ichimoku Kijun on the daily timeframe holds at $38.27, just under the current level, signaling nearby support. Daily momentum signals are mixed: MACD and ADX are neutral to negative, while RSI and CCI are neutral to positive; Stoch RSI is neutral. Bull/Bear Power (BBP) displays a strong buy signal, indicating near-term buyer persistence, but increased volatility and persistent selling pressure are seen as the price tests the lower end of today’s range.

Sideways bias as volatility bands limit breakout potential

In the short term, NVO is expected to trade within a volatility band of $37.80 to $39.40. The baseline scenario is sideways consolidation between $38.00 and $39.00. A break above $39.40 would indicate potential for higher resistance levels if short-term buyers emerge. Should the price fall below $37.80, further declines could follow, according to prevailing weekly and daily indicator signals.

Anton Kharitonov, expert at Traders Union, sees Novo Nordisk under pressure from both technical and fundamental angles. The price remains below all key moving averages, and external factors like restructuring costs and new competition in the obesity drug space are strong headwinds. The analyst is skeptical about near-term upside while sideways consolidation dominates and selling pressure persists. "Base case remains a choppy range between $38.00 and $39.00 — until price breaks out, I stay neutral and defensive here."

Earlier, analysts noted that Novo Nordisk faced continued selling pressure and technical overbought signals, suggesting a cautious outlook. This new wave of negative guidance and fresh competition in the obesity drug market amplifies downside risk, making a decisive move below the $37.80 support level a key signal for traders to monitor.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.